Clinical Trials Browser

Phase 3 × Ado-Trastuzumab Emtansine × Clear all

NCT04873362 2026-03-04

Astefania

Phase 3 Active not recruiting

Breast Neoplasms

NCT05415215 2026-02-10

ProHer

Phase 3 Completed

346 enrolled 20 charts

Breast Neoplasms, Patient Preference, Inflammatory Breast Neoplasms

NCT03975647 2025-12-10

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

Phase 3 Active not recruiting

466 enrolled 17 charts

HER2-positive Breast Cancer

NCT03529110 2025-10-21

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

Phase 3 Active not recruiting

524 enrolled 11 charts 1 FDA

Breast Neoplasms

NCT07008976 2025-08-14

Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer

Phase 3 Recruiting

Breast Neoplasms

NCT04740918 2025-08-08

KATE3

Phase 3 Terminated

96 enrolled 16 charts

Breast Neoplasms

NCT01772472 2025-07-22

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

Phase 3 Completed

1,486 enrolled 37 charts 1 FDA

Breast Neoplasms

NCT04622319 2025-05-09

DESTINY-Breast05

Phase 3 Active not recruiting

HER2-Positive Primary Breast Cancer

NCT06126640 2025-05-02

A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy

Phase 3 Recruiting

HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy

NCT06846437 2025-03-24

JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer

Phase 3 Recruiting

Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants

NCT03726879 2024-11-05

IMpassion050

Phase 3 Completed

454 enrolled 28 charts

Breast Neoplasms

NCT01120184 2024-03-04

A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)

Phase 3 Completed

1,095 enrolled 46 charts

Breast Neoplasms

NCT05755048 2023-09-01

FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Phase 3 Unknown

Breast Neoplasms

NCT03084939 2023-05-06

Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT05429684 2022-06-23

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

Phase 3 Unknown

HER2+ Breast Cancer

NCT01702571 2022-04-04

A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Phase 3 Completed

2,185 enrolled 20 charts

Breast Neoplasms

NCT02144012 2017-03-07

A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer

Phase 3 Terminated

49 enrolled 16 charts

Breast Neoplasms

NCT00829166 2016-10-31

EMILIA

Phase 3 Completed

991 enrolled 26 charts

Breast Neoplasms

NCT01419197 2016-10-12

TH3RESA

Phase 3 Completed

602 enrolled 15 charts

Breast Neoplasms